MYC and ovarian carcinoma: Results demonstrated that miRNA-200c-3p reduced PD-L1, c-Myc, and β-catenin expression levels, which sensitized ovarian cancer cells to both types of treatment and was associated with less tumorigenic microenvironment [70].